Page 3 - Glenmark Pharma

Glenmark gets USFDA nod for pneumonia treatment generic drug Atovaquone

he approved drug is a generic version of GlaxoSmithKline's Mepron Oral Suspension of similar strength

Little cheer for Glenmark Pharma as analysts expect stock to remain subdued

Lack of new product launches, high debt, changing US market are major worries

R&D spend will continue to be around 12% of revenue, says Glenmark CMD

A bigger chunk of our R&D investment is towards our innovative and specialty pipeline, said CMD

Glenmark Pharma announces launch of hair growth formula Nourkrin in Russia

Glenmark Pharmaceuticals Thursday announced the launch of Nourkrin, used to treat hair loss, in the Russian market. The product catering to both male and female patients will be exclusively marketed in Russia by Glenmark Impex LLC, a subsidiary of the company, under a licensing agreement with Denmark's Pharma Medico ApS. Glenmark has already launched Nourkrin Woman in India early this year. "It is a much-awaited product, as the problem of hair loss affects quite a significant proportion of the population. Glenmark has a strong portfolio of dermatology products in Russia... Nourkrin will be a great addition to this portfolio, Csaba Kantor, Senior Vice President & Head - Asia, Russia & CIS, Glenmark Pharmaceuticals, said in a statement. According to a survey conducted by market research firm GfK in 2017, 18.7 million women and 14.1 million men in Russia experienced hair loss over the preceding 12 months. Nourkrin Woman and Nourkrin Man, available as tablets, are an easy-to-use .

Glenmark arm gets approval for generic version of asthma drug in Germany

The company has already launched this product in Denmark, Sweden and Norway

Glenmark Pharma gets final nod from USFDA for cholesterol lowering drug

The approved product is a generic version of Daiichi Sankyo Inc's Welchol

US price erosion: Pressure on Glenmark's business to continue

Company expects 10-12 per cent price erosion to continue in America

Glenmark Pharma gets USFDA nod for scalp and skin treatment drug

The company's current portfolio consists of 133 products authorised for distribution at the US marketplace and 60 abbreviated new drug applications pending approval with the USFDA

Glenmark Pharma Q3 net drops 78% to Rs 1.04 bn; US business declines 40%

Glenmark's consolidated revenue also declined by 13.07 per cent at Rs 22.03 billion for the third quarter ended December 31

New launches near-term triggers for Glenmark

Risk-reward remains favourable as current tepid growth is factored in

Sun Pharma, Dr Reddy's, Glenmark gain even after price-fixing charges in US

Nifty Pharma index, the largest gainer among sectoral indices, was up 2.8%, as compared to unchanged in Nifty 50 index at 10,441 at 09:46 AM

Recent approvals to help Glenmark Pharma scale up FY18 growth

Glenmark Pharmaceuticals has gained over five per cent since its lows this month on brokerage upgrades which highlight the upside from product launches in the US and potential of out-licensing deals. Prior to the upgrades, the stock was under pressure given expectations of drug price erosion of 10-15 per cent in FY18 and falling contribution from generic version of Zetia, a drug used in bringing down cholesterol levels. The six month sales under exclusivity for this drug came to an end in the June quarter and generated about $175 million in revenues for Glenmark. In fact, one of the reasons for the company's overall revenues growing at 20 per cent year-on-year and operating profit rising 42 per cent in FY17 was due to Zetia sales.Barring Zetia and India business, performance in the June quarter was nothing to write home about. What had compounded matters was the currency depreciation in Latin American market and discontinuing sales in Venezuela resulting in a 31 per cent decline in ...

Glenmark Pharma: Recent approvals to help scale up FY18 growth

Upfront payments from out licensing deals could be the other trigger

Glenmark expects generics to drive growth over next 3-4 years

Focus in emerging markets will be to invest in product pipeline in dermatology, respiratory, oncology therapy

Glenmark Pharma gets USFDA nod for generic skin ointment

The ointment is used for treating skin inflamation

Glenmark Pharma Q1 net up 47% at Rs 333 cr on sales growth

Glenmark posted 47 per cent increase in consolidated net profit in Q1 FY 18 on the back of growth in sales in domestic and US markets. Net profit for the period was Rs 333 crore as against Rs 226 crore for same period last year.Overall revenue rose around 20 per cent to Rs 2363 crore led by growth in US and domestic market sales. While other companies have seen their domestic sales fall due to good and service tax related de-stocking in June, Glenmark reported 15 per cent growth in its India sales.Glenmark had seen a modest 6.8 per cent growth in domestic sales in January-March quarter. Growth was strong in April-May with some of the sales from preceding quarter materialising in the two months. Glenmark also has a strong portfolio of cardiac and anti diabetes drugs which were relatively less impacted due to destocking in June.The domestic and US business accounts for around 70 per cent of its consolidated revenue. The US sales have been boosted due to generic version of anti ...

Glenmark Pharma gets USFDA approval for skin cream generic

Glenmark Pharmaceuticals has received final approval from the US health regulator for generic version of Desonide cream, used to treat a variety of skin conditions. "Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (US FDA) for Desonide Cream, 0.05 per cent, the generic version of Desonide Cream, 0.05 per cent of Perrigo New York Inc," Glenmark Pharmaceuticals said in a BSE filing. According to IMS Health sales data for the 12 months to May 2017, Desonide Cream, 0.05 per cent, achieved annual sales of approximately USD 44.6 million, Glenmark said. The company's current portfolio consists of 120 products authorised for distribution in the US marketplace and 65 Abbreviated New Drug Applications (ANDA) pending approval with the USFDA. Glenmark Pharmaceuticals shares were trading up by 0.87 per cent at Rs 694.90 on the BSE.

Glenmark, Cyndea Pharma to develop complex drugs for US, Canada markets

Glenmark has tied up with Spanish firm Cyndea Pharma to develop complex drugs for US and Canada markets. Following the tie up Glenmark will develop soft-gelatin capsule products under technology license from the Spanish drug maker. The partnership allows Glenmark to expand its dosage forms and launch new products. Glenmark earns over 35 per cent revenue from US but the market is seeing increased competition and pricing pressure. Developing technology for soft-gelatin capsules in house would have taken longer and the tie up will quicken product launches for Glenmark.Glenmark's president (North America) Robert Matsuk said as many as 70 per cent of the small molecule pharmaceuticals are difficult for body to absorb which leads to challenges in developing effective oral formulations for these medicines. "The use of soft-gelatin capsules have wide applications to improve absorption and bio-availability of these medicines. Accessing this formulation and manufacturing technology with our ..

Glenmark Pharma climbs nearly 7% on smart Q3 earnings, robust sales in US

The stock climbed 6.86 per cent to Rs 970.25 on BSE

Glenmark to focus on specialty drugs to beat tackle price erosion in US

Drug maker draws $300 mn capex plan and higher R&D spend, focuses on differentiated dosage forms and inlicensing of complex drugs